Vaz-Salgado, Maria AngelesCigarral-Garcia, BelenFernandez-Perez, IsauraJimenez-Munarriz, BeatrizSampedro-Domarco, PaulaHernandez-Gonzalez, AinhoaVieito-Villar, MariaLuque-Caro, RaquelVillamayor-Delgado, Maria LuisaSepulveda-Sanchez, Juan Manuel2025-11-032025-11-032024-04-25Vaz-Salgado MÁ, García BC, Pérez IF, Munárriz BJ, Domarco PS, González AH, et al. SEOM-GEINO clinical guidelines for grade 2 gliomas (2023). Clin Transl Oncol. 2024 Nov;26(11):2856-28651699-3055https://hdl.handle.net/10668/28621The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AstrocytomaGuidelineIDH mutationLow-grade gliomaNeuro-oncologyOligodendrogliomaOligodendrogliomaIsocitrate DehydrogenaseAstrocytomaMutationWorld Health Organizationresearch article38662171open accessEnfoque GRADENeoplasias EncefálicasManipulación QuiroprácticaQuimioterapia Combinada10.1007/s12094-024-03456-xPMC11467015